Lung Cancer

Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).

Lung Cancer

Lung cancer is a common and very serious form of cancer, with more than 40,000 people diagnosed with the condition each year in the UK. The symptoms of lung cancer do not present in the early stages, but when symptoms do eventually present, they usually include the following:

Lung Cancer Genetics

How to Prevent Lung Cancer

Lung Cancer Treatments

What Causes Lung Cancer in Non-Smokers?

Secondary Lung Cancer

Carcinogens in Cigarette Smoke

Exploring Diversity in Lung Cancer: Impact on Incidence, Prognosis, and Treatment Strategies

Lung Cancer Diagnosis

Lung Plethysmography Procedure

Lung Cancer Questions

Lung Cancer and Electrolyte Imbalances

See more featured articles »

Everything You Need to Know About Giving Up Cigarettes

Palliative and End-of-Life Care in Lung Cancer

Lymph Nodes in Lung Cancer

What are the Survival Rates for Lung Cancer?

Lung Cancer Pathogenesis

Lung Cancer in Women: Understanding the Increasing Risk

Lung Cancer Screening Procedure

Lung Cancer Causes

Lung Cancer Symptoms

Immunotherapy: The Future of Lung Cancer Treatment?

Epidemiology of Lung Cancer

Pulmonary Resection in Lung Cancer

Pulmonary Transplant (Lung Transplant)

Lung Cancer Risk Factors

Types of Lung Cancer Surgery

Lung Cancer: Radiotherapy and Chemotherapy

Lung Cancer Research

Latest Lung Cancer News and Research

Wildfire smoke may be more harmful than other air pollution, two Mount Sinai studies find

As climate change drives more frequent and intense wildfires, researchers at the Icahn School of Medicine at Mount Sinai have published two large-scale studies showing that wildfire smoke may pose greater health risks than other sources of air pollution, with higher risks of hospitalization for cardiovascular and respiratory disease and poorer survival among patients with lung cancer.

18 Sep 2026

Diaceutics launches Precision for All Strategic Collaboration at Fierce Pharma Week 2026

Intelligence and engagement company, Diaceutics, is bringing together senior voices from across the biopharmaceutical industry at the Precision for All Strategic Collaboration, launching at Fierce Pharma Week 2026.

From Diaceutics PLC 18 Sep 2026

Study identifies powerful inherited risk factor for lung cancer

A rare inherited mutation in the Epidermal Growth Factor Receptor (EGFR) gene is associated with a 25-fold increased risk of lung cancer, according to a study by investigators at Dana-Farber Cancer Institute and 23andMe Research Institute.

17 Sep 2026

Wildfire smoke poses greater health risks than other pollution

17 Sep 2026

Existing anti-seizure drug slows the growth of diffuse midline gliomas

An existing anti-seizure drug slows the growth of a devastating group of childhood cancers, new Stanford Medicine-led research has shown.

17 Sep 2026

AI tools help predict immunotherapy outcomes in lung cancer patients

Artificial intelligence (AI) tools can help physicians predict treatment and survival outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy, according to a new study published in Nature Medicine.

16 Sep 2026

Lung Facts updated with latest evidence on respiratory disease across 21 countries

The International Respiratory Coalition (IRC) has updated its Lung Facts platform with the latest evidence on the burden of respiratory disease across 21 countries, providing policymakers, clinicians and patient advocates with updated data to drive national-level policy action on lung health.

16 Sep 2026

Genomic profiling uncovers distinct TP53 and PI3K pathways across tumor budding grades

A newly proposed International Association for the Study of Lung Cancer (IASLC) tumor budding-based grading system successfully identified patients with resected lung squamous cell carcinoma (SqCC) at higher risk of poor outcomes and showed potential to help guide selection for adjuvant chemotherapy, according to research presented at the IASLC 2026 World Conference on Lung Cancer on Lung Cancer. (WCLC).

15 Sep 2026

Stage 1 findings support continued pivotal phase evaluation of gotistobart

Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti-CTLA-4 antibody gotistobart compared with 10.0 months for patients receiving docetaxel, according to updated findings from Stage 1 of the Phase 3 PRESERVE-003 trial.

15 Sep 2026

Mobile LDCT lung cancer screening can reach vulnerable populations in resource-limited settings

Mobile low-dose computed tomography (LDCT) screening can reach high-risk and socially vulnerable populations in resource-limited settings, according to initial results from the Third Brazilian Early Lung Cancer Trial (BRELT3) presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Research identifies novel prognostic biomarkers for class II and III BRAF-altered cancers

Patients with metastatic non-small cell lung cancer (NSCLC) harboring class II and class III BRAF alterations have distinct clinicopathologic and genomic characteristics, with class III alterations potentially associated with worse prognosis, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Early consolidative SRT shows value in EGFR-mutant NSCLC with limited brain metastases

Early cranial stereotactic radiotherapy (SRT) administered with first-line osimertinib was associated with improved intracranial control and survival outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC) and limited brain metastases, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Final results from PAPILLON trial confirm long-term survival in a subset of lung cancer

Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit and the longest median overall survival reported to date for people with the disease.

15 Sep 2026

Zipalertinib plus chemotherapy improves survival in advanced NSCLC harboring EGFR exon 20 insertion mutations

Adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival in patients receiving first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Brain MRI surveillance without prophylactic cranial irradiation reduces cognitive failure risk in patients with SCLC

In the SWOG S1827 MAVERICK phase III randomized trial, patients with small-cell lung cancer (SCLC) who underwent regular brain MRI surveillance without prophylactic cranial irradiation (PCI) had significantly better cognitive failure–free survival (the primary endpoint of the trial), without an apparent difference in overall survival, according to results presented at the Presidential Symposium of the IASLC 2026 World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer, in Seoul, Republic of Korea.

15 Sep 2026

Adjuvant osimertinib delivers long-term survival benefit in EGFR-mutated NSCLC

An exploratory eight-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely resected, EGFR-mutated stage IB-IIIA non-small cell lung cancer (NSCLC).

15 Sep 2026

T-DXd significantly extends progression-free survival in HER2-mutant NSCLC

First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), according to primary results from the Phase 3 DESTINY-Lung04 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Zidesamtinib shows strong activity in TKI-naive ROS1-positive non-small cell lung cancer

New results from the global Phase I/II ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received a tyrosine kinase inhibitor (TKI).

15 Sep 2026

Sacituzumab govitecan combination misses progression-free survival endpoint in metastatic NSCLC

Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) and PD-L1 tumor proportion score (TPS) of 50% or greater, according to primary results from the Phase 3 EVOKE-03/KEYNOTE-D46 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Tam-Peli significantly extends survival in relapsed small-cell lung cancer

The phase III TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCLC).

14 Sep 2026